Bio-Identical Hormones in Menopausal treatment is fastest growing segment fueling the growth of Bio-Identical Hormones Market
Bio-identical Hormones Market |
Market Overview:
Bio-identical hormones provide a
natural alternative to treat symptoms associated with menopause in women and
andropause in men. These hormones have identical chemical and molecular
structure as endogenous hormones in the human body. They are used to treat
issues like hot flashes, night sweats, osteoporosis, and mood swings in peri
and post menopausal women and andropausal men.
The global Bio-Identical Hormones
Market is estimated to be valued at US$
9.08 Bn in 2023 and is expected to exhibit a CAGR of 5.2% over the forecast period 2023 to 2030, as highlighted
in a new report published by Coherent Market Insights.
Market key trends:
The growing geriatric population
base and increasing prevalence of hormonal deficiencies worldwide are major
drivers for the bio-identical hormones market growth. As per the United Nations
Department of Economic and Social Affairs aging population report, the number
of people aged 65 years and above are projected to grow from 703 million in
2019 to 1.5 billion in 2050 globally. This aging demographic is more
susceptible to develop hormonal imbalances and related health issues. Hence,
the demand for bio-identical hormones for treatment of menopause symptoms in
women and andropause in men is significantly increasing.
Furthermore, growing awareness
about adverse effects of synthetic hormones and benefits of bio-identical
hormones are encouraging consumers to opt for natural alternatives, which is
positively impacting the market growth.
Segment Analysis
The global bio-identical hormones
market is segmented into type, application, route of administration and end
user. Based on type, the market is segmented into estrogens, progesterone and
testosterone. Among these, the estrogens segment dominates the market due to
increasing prevalence of postmenopausal symptoms in women. Estrogens such as
estradiol are widely used as hormone replacement therapy (HRT) to reduce these
symptoms.
Key Takeaways
The Global
Bio-identical Hormones Market Size is expected to witness high growth,
exhibiting a CAGR of 5.2% over the
forecast period, due to increasing incidence of hormonal imbalance disorders
and popularity of bio-identical hormones as a safer alternative to traditional
hormone therapies.
Regional analysis: North America holds the major share in the
global market and is expected to dominate the market during the forecast
period. This is attributed to growing awareness and favorable reimbursement
policies for bio-identical hormone therapies in the region.
Key players: Key players operating in the bio-identical hormones
market include Noven Pharmaceuticals, Novartis AG, Sottepolle, BioTE Medical,
Pfizer Inc., TherapeuticsMD Inc, Bayer AG, and Novo Nordisk A/S. Among these,
Noven Pharmaceuticals leads the market owing to its diverse product portfolio
and strong distribution network across regions.
Get More Insights Here
https://www.newsstatix.com/bio-identical-hormones-market-share-size-forecast-outlook-2023-2030/
Comments
Post a Comment